Biocon Limited said that its subsidiary Biocon Biologics has been given an exclusive license from Adagio Therapeutics, a US-based biotech company, for manufacturing and commercializing an antibody treatment based on ADG20 for India and certain emerging markets.

ADG20 is a novel monoclonal antibody that targets the spike protein of SARS-CoV-2 and related coronaviruses. It is in global clinical development by Adagio Therapeutics as a single agent for the treatment and prevention of Covid-19, its variants, and any future variants that could emerge.

According to Biocon, ADG20’s initial data suggests that the monoclonal antibody can give quick and durable protection against Covid-19 for up to a year. This makes it an appropriate agent for preventing infections and considerably bring down Covid-19 related hospitalizations and deaths, said the Indian biopharma company.

Kiran Mazumdar-Shaw – Executive Chairperson of Biocon Biologics said: “We are very proud to partner with Adagio in our shared mission to provide affordable access to a best-in-class antibody therapy for people affected by SARS-CoV-2.

“This partnership with Adagio aligns our joint vision of bringing superior biologic therapies to millions of patients in low and middle income countries. Vaccines alone will not protect and make the world safer. Biologic therapies that arrest the virus in its path of devastation are a necessity for sustainable protection and safety.”

  Adagio Therapeutics, ADG20, Biocon, Biocon Biologics, Coronavirus, COVID-19, India, Kiran Mazumdar-Shaw, SARS-CoV-2, USA